Assess Complete Response (CR) rate in BRAFV600 mutation positive metastatic melanoma patients who have received vemurafenib plus HD IL-2 at 10 (±3) weeks and 26 (±3) weeks from the start of HD IL-2 dosing.
18 Years and older (Adult, Senior)
September 11, 2012
February 5, 2015
University Arizona Cancer Center Tucson, Arizona, United States
Moores UCSD Cancer Center La Jolla, California, United States
MSMC Research Program Miami Beach, Florida, United States
(and 18 more...)
† Study has passed its completion date and status has not been verified in more than two years.